Rothschild & Co Redburn initiated coverage of Balchem with a Neutral rating and $162 price target. The company has a "resilient" business model built upon niche high-growth products, the analyst tells investors in a research note. However, the firm finds Balchem's valuation as "rich" at current share levels.
